Clinical trials: Myasthenia Gravis (MG)
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
System Lupus Erythematosus(SLE), Scleroderma
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the…
- Conditions
- System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG)
- Trial name
- NCT07470151
- Testing
- EVM18001 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Generalized Myasthenia Gravis
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
A randomized, double-blind, placebo-controlled multicenter study evaluating the safety and efficacy of Rituximab (Mabthera®) in patients with new onset generalized myasthenia gravis (MG).
- Trial name
- Rinomax (NCT02950155)
- Testing
- Rituximab, Sodium Chloride solution
- Where
- Sweden
- Volunteers
- 47 people
- Sponsor
- Fredrik Piehl
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG)
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
- Trial name
- ADAPT Forward2 (NCT07673627)
- Testing
- Empasiprubart IV, Efgartigimod PH20 SC PFS
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 40 people
- Sponsor
- argenx
Myasthenia Gravis, Generalized
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
- Trial name
- MG-ARCADIA (NCT06909253)
- Testing
- Ravulizumab
- Where
- 11 sites in Poland
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Myasthenia Gravis (MG)
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor.
- Trial name
- ROME-MG (NCT07787247)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- George Washington University
Myasthenia Gravis, Depression
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG.
- Conditions
- Myasthenia Gravis, Depression, Thymoma, Depression and Quality of Life
- Trial name
- NCT07649187
- Testing
- Psychological counseling intervention
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Ming-Hsing Chang
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Myasthenia Gravis
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider.
- Trial name
- NCT07217509
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- CorEvitas
Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
- Trial name
- NCT06967480
- Testing
- Ravulizumab
- Where
- 23 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis (gMG)
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
- Trial name
- NCT06359041
- Testing
- CABA-201
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cabaletta Bio
Myasthenia Gravis, Fatigue
Capturing Key MG-symptoms Using Smartphone Recordings.
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.
- Trial name
- CAPTURE - MG (NCT06743490)
- Where
- 2 sites in Netherlands
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Myasthenia Gravis
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
This was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe…
- Trial name
- URSA (NCT05132569)
- Testing
- Tolebrutininb
- Where
- 22 sites in United States, Canada and 7 more
- Volunteers
- 6 people
- Sponsor
- Sanofi
Myasthenia Gravis
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China
- Trial name
- NCT04346888
- Testing
- HBM9161 Injection (680mg and 340 mg), HBM9161 Injection (340 mg)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
Vitaccess Real MG Registry
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL).
- Trial name
- VRMG (NCT06064461)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Vitaccess Ltd
Myasthenia Gravis, Generalized
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
- Trial name
- NCT04146051
- Testing
- Descartes-08
- Where
- 15 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Cartesian Therapeutics
Myasthaenia Gravis
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis.
- Trial name
- NCT06799247
- Testing
- Decartes-08
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 128 people
- Sponsor
- Cartesian Therapeutics
Myasthenia Gravis, Ocular, Gene Polymorphism
Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and…
- Trial name
- NCT05380128
- Testing
- Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
- Where
- China
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Myasthenia Gravis
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
The purpose of the study is to investigate the efficacy and safety for steroid resistant, non-thymectomized MG patients.
- Trial name
- NCT00309101
- Testing
- tacrolimus
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Astellas Pharma Inc
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance